

Consolidated Financial Results for Fiscal 2017

(Reference Data of Financial Statements for the 3Q of Fiscal 2017)

February 1, 2018

KAKEN PHARMACEUTICAL CO., LTD.

Corporate Communications

Tel: +81-(0)3-5977-5002

Fax: +81-(0)3-5977-5131

Email: koho@kaken.co.jp

1. Summary of Consolidated Financial Statements for the Third Quarter of Fiscal 2017

(Figures less than one million yen have been omitted)

	FY2016 3rd Q	FY2016	FY2017 3rd Q	Y o Y increase (decrease)		FY2017 Forecasts	Y o Y increase (decrease)	
				Yen	%		Yen	%
Net sales	78,965	101,479	76,891	(2,074)	97.4%	101,700	221	100.2%
Operating profit	24,953	30,707	23,706	(1,246)	95.0%	26,800	(3,907)	87.3%
Ratio of net sales	31.6%	30.3%	30.8%			26.4%		
Ordinary profit	25,232	30,981	24,062	(1,170)	95.4%	27,000	(3,981)	87.1%
Ratio of net sales	32.0%	30.5%	31.3%			26.5%		
Profit	17,983	22,017	16,859	(1,124)	93.7%	19,100	(2,917)	86.8%
Ratio of net sales	22.8%	21.7%	21.9%			18.8%		
Comprehensive income	18,782	22,587	18,481	(301)	98.4%			
R&D expenses	4,985	6,450	5,778	793	115.9%	10,900	4,450	169.0%

2. Breakdown of Sales by Main Pharmaceuticals and Medical Devices

(Figures less than one million yen have been omitted)

	FY2016 3rd Q	FY2016	FY2017 3rd Q	%	FY2017 Forecasts	%
Anti-osteoarthritis Artz	23,056	28,978	22,960	99.6%	29,700	102.5%
Anti-nail fungus Clenafin	17,349	21,624	17,897	103.2%	23,100	106.8%
Post-operative anti-adhesive Seprafilm	8,584	11,036	8,037	93.6%	10,800	97.9%
Anti-hyperlipidemia Lipidil	3,436	4,430	3,502	101.9%	4,600	103.8%
Wound healing agent Fiblast Spray	2,782	3,700	2,746	98.7%	3,900	105.4%
Generic products	9,195	11,903	9,192	100.0%	12,200	102.5%